Sameer joined atai Life Sciences in 2022.
Previously, Sameer was a Manager at Bristol Myers Squibb where he was responsible for the financial analysis of development options and provided insights into tradeoffs among the options, with the goal of enabling value-driven R&D decisions. Sameer quantified technical and regulatory risks and integrated this risk assessment alongside projections of commercial revenues, and costs, in order to value R&D investments for portfolio planning.
Before that, he was a Consultant at Bionest Partners, a boutique life science strategy consulting firm. While at Bionest, Sameer advised 30+ US and EU pharma and biotech companies on commercial strategies including pipeline prioritization, commercial launch strategies, opportunity assessments, competitive simulations, and stakeholder engagement roadmaps.
Sameer holds a Bachelors of Science in Biomedical Engineering with a Minor in Biology from the University of Rochester and a Masters of Science in Biotechnology Enterprise and Entrepreneurship from Johns Hopkins University.